ArticleClinical and experimental nephrology2026
Zinc deficiency is associated with erythropoietin-stimulating agents hyporesponsive anemia in peritoneal dialysis patients: a cross-sectional study.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZinc deficiency is widely recognized as a cause of anemia, but no studies have clarified the impact of zinc deficiency on achieving target hemoglobin levels in patients undergoing peritoneal dialysis (PD) and receiving high-dose erythropoiesis-stimulating agent (ESA) therapy. This study aimed to investigate the relationship between zinc deficiency and ESA-hyporesponsive anemia in patients on PD.
methodsThis cross-sectional study included 164 patients on PD aged ≥ 18 years. The target hemoglobin level was 11-13 g/dL. ESA dosage was categorized as low-dose (< 120 µg/month) or high-dose (≥ 120 µg/month), while zinc deficiency was defined as a serum zinc level < 60 µg/dL. A logistic regression model was used to calculate the odds ratio (OR) for achieving the target hemoglobin level.
resultsThe proportion of patients achieving the target hemoglobin level was 48.2% in the low-dose ESA and non-zinc-deficient group, and 12.2% in the high-dose ESA and zinc-deficient group. Compared with the low-dose ESA and non-zinc-deficient group, the adjusted OR for achieving the target hemoglobin level was significantly lower in the high-dose ESA and zinc-deficient group (OR: 0.19, 95% confidence interval 0.05-0.72). Stratified analyses based on serum albumin, serum C-reactive protein, and transferrin saturation did not change the association between the high-dose ESA and zinc-deficient group and the achievement of the target hemoglobin level.
conclusionZinc deficiency in patients on PD is a significant barrier to achieving the target hemoglobin level, and serum zinc levels should be routinely monitored in patients with ESA-hyporesponsive anemia.
Indexed as
Identifiers
41609958What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.